Kevin T McDermott (Kevin McDermott)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Systematic Review

Early Breast Cancer

Respiratory Syndrome Coronavirus

Top Venues

Systematic reviews

PharmacoEconomics

This page only lists publications with an associated author ORCID identifier.

Publications

Kevin T McDermott, Mark Perry, Willemijn Linden, Rachel Croft, Robert Wolff, Jos Kleijnen
The quality of COVID-19 systematic reviews during the coronavirus 2019 pandemic: an exploratory comparison. Systematic reviews 13 (1) (2024)
Kevin T McDermott, Mark Perry, Willemijn Linden, Rachel Croft, Robert Wolff, Jos Kleijnen
The quality of COVID-19 systematic reviews during the coronavirus 2019 pandemic: an exploratory comparison. Systematic reviews 13 (1) (2024)
Giovany Orozco-Leal, Nigel Armstrong, Ashleigh Kernohan, Charlotte Ahmadu, Diarmuid Coughlan, Kevin T McDermott, Steven Duffy, Susan O'Meara, Tomos Robinson, Luke Vale, Jos Kleijnen
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics (2023)
Giovany Orozco-Leal, Nigel Armstrong, Ashleigh Kernohan, Charlotte Ahmadu, Diarmuid Coughlan, Kevin T McDermott, Steven Duffy, Susan O'Meara, Tomos Robinson, Luke Vale, Jos Kleijnen
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics (2023)